Trial · NCT02720068
Participant flow108
How many started, completed or left each group, period by period.
1 to 20 of 108
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Part A: Favezelimab 7 mg Monotherapy | 3 | |
| Overall Study | STARTED | Part A: Favezelimab 21 mg Monotherapy | 6 | |
| Overall Study | STARTED | Part A: Favezelimab 70 mg Monotherapy | 3 | |
| Overall Study | STARTED | Part A: Favezelimab 210 mg Monotherapy | 3 | |
| Overall Study | STARTED | Part A: Favezelimab 700 mg Monotherapy | 3 | |
| Overall Study | STARTED | Part A: Favezelimab 7 mg + Pembrolizumab 200 mg | 3 | |
| Overall Study | STARTED | Part A: Favezelimab 21 mg + Pembrolizumab 200 mg | 3 | |
| Overall Study | STARTED | Part A: Favezelimab 70 mg + Pembrolizumab 200 mg | 3 | |
| Overall Study | STARTED | Part A: Favezelimab 210 mg + Pembrolizumab 200 mg | 3 | |
| Overall Study | STARTED | Part A: Favezelimab 700 mg + Pembrolizumab 200 mg | 3 | |
| Overall Study | STARTED | Part B: Favezelimab 800 mg Monotherapy (Arm 1) | 21 | |
| Overall Study | STARTED | Part B: Favezelimab 200 mg + Pembrolizumab 200 mg (Arm 2A) | 206 | |
| Overall Study | STARTED | Part B: Favezelimab 700 mg + Pembrolizumab 200 mg (Arm 2B) | 40 | |
| Overall Study | STARTED | Part B: Favezelimab 800 mg + Pembrolizumab 200 mg (Arm 2C) | 41 | |
| Overall Study | STARTED | Part B: MK-4280A (Arm 5) | 59 | |
| Overall Study | STARTED | Part B: Favezelimab 800 mg + Pembrolizumab 200 mg + mFOLFOX7 (Arm 3) | 20 | |
| Overall Study | STARTED | Part B: Favezelimab 800 mg + Pembrolizumab 200 mg + FOLFIRI (Arm 4) | 21 | |
| Overall Study | STARTED | Part B: Favezelimab 800 mg + Pembrolizumab 200 mg + Lenvatinib 20 mg (Arm 6) | 40 | |
| Overall Study | Treated | Part A: Favezelimab 7 mg Monotherapy | 3 | |
| Overall Study | Treated | Part A: Favezelimab 21 mg Monotherapy | 6 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02720068/flow